Quetiapine XR in Schizophrenic Patients

This study has been terminated.
(Planned number of 30 subjects could not be recruited during recruitment phase.)
Sponsor:
Collaborators:
Hannover Clinical Trial Center GmbH
AstraZeneca
Information provided by (Responsible Party):
Wolfgang Dillo, Hannover Medical School
ClinicalTrials.gov Identifier:
NCT01071135
First received: February 18, 2010
Last updated: November 10, 2011
Last verified: August 2011
  Purpose

The purpose of the study is to determine the effect of Quetiapine in patients with schizophrenia induced by cannabis abuse.


Condition Intervention Phase
Schizophrenia
Drug: Quetiapine XR
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study-

Resource links provided by NLM:


Further study details as provided by Hannover Medical School:

Primary Outcome Measures:
  • Reduction in PANSS total score [ Time Frame: within 3 months ] [ Designated as safety issue: No ]
    The primary variable will be the proportion of patients with a 30% reduction from screening visit to month 3 in PANSS total score.


Enrollment: 5
Study Start Date: September 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Quetiapine XR Drug: Quetiapine XR
Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.

Detailed Description:

To evaluate the effect of quetiapine on positive and negative symptoms of schizophrenia on schizophrenic patients associated with cannabis abuse and patients with psychotic disorders through cannabis abuse.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females and/or males aged 18 to 60 years.
  2. Provision of written informed consent. In case of acute psychosis written informed consent has to be obtained from the legal representative of the patient, if applicable or from two independent physicians not involved in the study. When the patient recovers, the written informed consent has to be signed by the patient itself.
  3. A diagnosis of schizophrenia (ICD10: F20.0, F20.1, F20.2, F20.4, F20.5) with associated cannabis abuse and/or psychotic disorders (e.g. schizophrenia) through cannabis (ICD 10: F12.5, F12.7).
  4. A score of at least 15 on the positive scale of the PANSS.
  5. Female patients of childbearing potential must be using a reliable method of contraception (i.e. contraceptive pill, contraceptive coil, sterilization, hysterectomy) and have a negative blood human chorionic gonadotropin (HCG) test at enrollment.
  6. Able to understand and comply with the requirements of the study. In case of acute psychosis only those patients are included that are expected to understand the requirements under healthy conditions.

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Any ICD10 F-criteria not defined in the inclusion criteria.
  3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to themselves or others.
  4. Known intolerance or lack of response to quetiapine fumarate as judged by the investigator.
  5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment, including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir.
  6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids.
  7. Patients who require treatment with one or more additional neuroleptics to quetiapine.
  8. Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation.
  9. Substance or alcohol dependence within 4 weeks prior to enrolment, at enrollment and during the study (except for cannabis, caffeine or nicotine dependence), as defined by DSM-IV criteria.
  10. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment.
  11. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator.
  12. An absolute neutrophil count (ANC) of ≤ 1.5 x 109 per liter.
  13. Involvement in the planning and conduct of the study.
  14. Previous enrollment or randomisation of treatment in the present study.
  15. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

    • Unstable DM as defined as enrollment glycosylated haemoglobin (HbA1c) >8.5%.
    • Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
    • Not under physicians care for DM.
    • Physicians responsible for patient´s DM care has not indicated that patient´s DM is controlled. Physician responsible for patient´s DM care has not approved patient´s participation in the study.
    • Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to inclusion. For thiazolidinediones (glitazones) this period should be at least 8 weeks.
    • Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks.

    Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.

  16. Previous treatment with study medication within the last 4 weeks prior to enrollment into this study.
  17. Participation in another drug trial within 4 weeks prior enrollment into this study or current participation in another clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01071135

Locations
Germany
Hannover Medical School
Hannover, Germany, 30625
Krankenhaus Lübbecke
Lübbecke, Germany, 32312
Klinikum Wahrendorff
Sehnde, Germany, 31319
Sponsors and Collaborators
Hannover Medical School
Hannover Clinical Trial Center GmbH
AstraZeneca
Investigators
Principal Investigator: Wolfgang Dillo, MD Hannover Medical School
  More Information

No publications provided

Responsible Party: Wolfgang Dillo, MD, Hannover Medical School
ClinicalTrials.gov Identifier: NCT01071135     History of Changes
Other Study ID Numbers: D1443C00018
Study First Received: February 18, 2010
Last Updated: November 10, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 22, 2014